Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents
暂无分享,去创建一个
Delong Liu | Yue-hua Ma | Delong Liu | S. Cang | Jiahuai Tan | Shundong Cang | Yuehua Ma | Richard L Petrillo | Jiahuai Tan | R. Petrillo | Delong Liu | Yuehua Ma | Shundong Cang | Jiahuai Tan | Richard L Petrillo | Jiahuai Tan | Yuehua Ma | Richard L Petrillo
[1] T. Vanhaecke,et al. Differential Effects of Histone Deacetylase Inhibitors in Tumor and Normal Cells—What Is the Toxicological Relevance? , 2005, Critical reviews in toxicology.
[2] G. Brosch,et al. Histone modifications and chromatin dynamics: a focus on filamentous fungi , 2008, FEMS microbiology reviews.
[3] S. Steinberg,et al. Clinical and Molecular Responses in Lung Cancer Patients Receiving Romidepsin , 2007, Clinical Cancer Research.
[4] J. Mariadason. HDACs and HDAC inhibitors in colon cancer , 2008, Epigenetics.
[5] A. V. van Kuilenburg,et al. Histone deacetylases (HDACs): characterization of the classical HDAC family. , 2003, The Biochemical journal.
[6] P. Atadja,et al. A phase I study of oral panobinostat (LBH589) alone and in combination with docetaxel (Doc) and prednisone in castration-resistant prostate cancer (CRPC) , 2008 .
[7] Benjamin A. Garcia,et al. Cathepsin L Proteolytically Processes Histone H3 During Mouse Embryonic Stem Cell Differentiation , 2008, Cell.
[8] C. Pérez-Plasencia,et al. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors , 2007, BMC Cancer.
[9] Karolin Luger,et al. Nucleosome and chromatin fiber dynamics. , 2005, Current opinion in structural biology.
[10] H. Hurwitz,et al. Phase I/II: The oral isotype-selective HDAC inhibitor MGCD0103 in combination with gemcitabine (Gem) in patients (pts) with refractory solid tumors , 2007 .
[11] K. Camphausen,et al. Enhancement of Xenograft Tumor Radiosensitivity by the Histone Deacetylase Inhibitor MS-275 and Correlation with Histone Hyperacetylation , 2004, Clinical Cancer Research.
[12] P. Atadja,et al. Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells. , 2008, Blood.
[13] Minoru Yoshida,et al. From discovery to the coming generation of histone deacetylase inhibitors. , 2003, Current medicinal chemistry.
[14] W. Stadler,et al. A phase II study of depsipeptide in refractory metastatic renal cell cancer. , 2006, Clinical genitourinary cancer.
[15] T. Naoe,et al. Apoptotic Cytotoxic Effects of a Histone Deacetylase Inhibitor, FK228, on Malignant Lymphoid Cells , 2000, Japanese journal of cancer research : Gann.
[16] P. Finn,et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. , 2008, The Biochemical journal.
[17] K. Chi,et al. Systemic therapy after first-line docetaxel in metastatic castration-resistant prostate cancer , 2008, Current opinion in supportive and palliative care.
[18] L. Cuppini,et al. The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells , 2007, Leukemia.
[19] M. Carducci,et al. Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] S. Adimoolam,et al. HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination , 2007, Proceedings of the National Academy of Sciences.
[21] D. Qian,et al. Targeting Tumor Angiogenesis with Histone Deacetylase Inhibitors: the Hydroxamic Acid Derivative LBH589 , 2006, Clinical Cancer Research.
[22] M. Lübbert,et al. Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells , 2008, Oncogene.
[23] R. Taulli,et al. Valproate enhances imatinib‐induced growth arrest and apoptosis in chronic myeloid leukemia cells , 2006, Cancer.
[24] V. Grégoire,et al. Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Jin Zhao,et al. Radiosensitization by the Histone Deacetylase Inhibitor PCI-24781 , 2007, Clinical Cancer Research.
[26] M. Caraglia,et al. Histone deacetylase inhibitors: a new wave of molecular targeted anticancer agents. , 2007, Recent patents on anti-cancer drug discovery.
[27] A. Zambrano,et al. Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer , 2008, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.
[28] M. Jeffers,et al. Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer , 2008, International journal of cancer.
[29] D. Vigushin,et al. Histone deacetylase inhibitors in cancer treatment. , 2002, Anti-cancer drugs.
[30] O. Witt,et al. Targeting histone deacetylases in neuroblastoma. , 2009, Current pharmaceutical design.
[31] M. Dokmanovic,et al. Prospects: Histone deacetylase inhibitors , 2005, Journal of cellular biochemistry.
[32] Andrew J. Bannister,et al. Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain , 2001, Nature.
[33] Wei-Guo Zhu,et al. The changing face of HDAC inhibitor depsipeptide. , 2009, Current cancer drug targets.
[34] L. Siu,et al. First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting , 2008, Journal of hematology & oncology.
[35] C. Steidl,et al. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia , 2005, Annals of Hematology.
[36] M. Grever,et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] M. Fanucchi,et al. Recent advances of novel targeted therapy in non-small cell lung cancer , 2009, Journal of hematology & oncology.
[38] S. Bates,et al. Phase I trial of romidepsin, a histone deacetylase inhibitor, given on days one, three and five in patients with thyroid and other advanced cancers , 2008 .
[39] Xiang-Jiao Yang,et al. Class II Histone Deacetylases: from Sequence to Function, Regulation, and Clinical Implication , 2005, Molecular and Cellular Biology.
[40] P. Dent,et al. Interactions between Bortezomib and Romidepsin and Belinostat in Chronic Lymphocytic Leukemia Cells , 2008, Clinical Cancer Research.
[41] Srinivas Annavarapu,et al. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. , 2005, Blood.
[42] P. Zinzani,et al. Phase II study of oral panobinostat (LBH589), a potent pan-deacetylase inhibitor, in patients with refractory Cutaneous T-cell Lymphoma (CTCL) , 2008 .
[43] E. Galanis,et al. Vorinostat in solid and hematologic malignancies , 2009, Journal of hematology & oncology.
[44] M. Grever,et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. , 2004, Blood.
[45] K. Luger. Dynamic nucleosomes , 2005, Chromosome Research.
[46] J. Doroshow,et al. Phase I Trial of MS-275, a Histone Deacetylase Inhibitor, Administered Weekly in Refractory Solid Tumors and Lymphoid Malignancies , 2007, Clinical Cancer Research.
[47] H. Hess-Stumpp. Histone deacetylase inhibitors and cancer: from cell biology to the clinic. , 2005, European journal of cell biology.
[48] P. Valagussa,et al. Phase II study of the histone-deacetylase inhibitor ITF2357 in relapsed/refractory Hodgkin’s lymphoma patients , 2008 .
[49] A. Hagenbeek,et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] M. Göttlicher. Valproic acid: an old drug newly discovered as inhibitor of histone deacetylases. , 2004, Annals of hematology.
[51] R. Schilsky,et al. Phase I study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the histone deacetylase inhibitor (HDACi) PCI-24781 , 2008 .
[52] Michael Rytting,et al. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. , 2006, Blood.
[53] M. Carducci,et al. Evaluation of the Pharmacodynamic Effects of MGCD0103 from Preclinical Models to Human Using a Novel HDAC Enzyme Assay , 2008, Clinical Cancer Research.
[54] O. Politz,et al. MS-275, a potent orally available inhibitor of histone deacetylases--the development of an anticancer agent. , 2007, The international journal of biochemistry & cell biology.
[55] J. Marshall,et al. A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. , 2002, Journal of experimental therapeutics & oncology.
[56] K. Camphausen,et al. Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid , 2005, International journal of cancer.
[57] Yue-hua Ma,et al. New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer , 2009, Journal of hematology & oncology.
[58] Takeshi Inoue,et al. Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo. , 2002, Biochemical pharmacology.
[59] D. Hallahan,et al. Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer. , 2006, Cancer research.
[60] I. Christensen,et al. Identification of predictive biomarkers for the histone deacetylase inhibitor belinostat in a panel of human cancer cell lines. , 2008, Cancer biomarkers : section A of Disease markers.
[61] Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. , 2007, Anti-cancer agents in medicinal chemistry.
[62] Zhenhao Hua,et al. Experimental study on inhibitory effects of histone deacetylase inhibitor MS-275 and TSA on bladder cancer cells. , 2010, Urologic oncology.
[63] V. Ogryzko,et al. Regulation of activity of the transcription factor GATA-1 by acetylation , 1998, Nature.
[64] L. Siu,et al. Promising antitumor activity with MGCD0103, a novel isotype-selective histone deacetylase inhibitor , 2008, Expert opinion on investigational drugs.
[65] D. Mottet,et al. Histone deacetylases: target enzymes for cancer therapy , 2007, Clinical & Experimental Metastasis.
[66] S. Berger. An embarrassment of niches: the many covalent modifications of histones in transcriptional regulation , 2001, Oncogene.
[67] P. Pandolfi,et al. Tolerability, Pharmacodynamics, and Pharmacokinetics Studies of Depsipeptide (Romidepsin) in Patients with Acute Myelogenous Leukemia or Advanced Myelodysplastic Syndromes , 2008, Clinical Cancer Research.
[68] Prim B. Singh,et al. Mammalian chromodomain proteins: their role in genome organisation and expression. , 2000, BioEssays : news and reviews in molecular, cellular and developmental biology.
[69] L. Borsu,et al. Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. , 2009, Cancer research.
[70] E. Sausville,et al. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. , 2007, Blood.
[71] K. Glaser. HDAC inhibitors: clinical update and mechanism-based potential. , 2007, Biochemical pharmacology.
[72] Junwu Zhang,et al. Important roles of reversible acetylation in the function of hematopoietic transcription factors , 2005, Journal of cellular and molecular medicine.
[73] R. Martell,et al. Treatment of relapsed or refractory non-hodgkin lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: Interim results from a phase II study , 2008 .
[74] D. Gandara,et al. Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[75] Jun Lu,et al. HDAC inhibitors: a potential new category of anti-tumor agents. , 2007, Cellular & molecular immunology.
[76] G. Kouraklis,et al. Histone deacetylase inhibitors and anticancer therapy. , 2002, Current medicinal chemistry. Anti-cancer agents.
[77] M. Morris,et al. Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[78] T. Barbui,et al. The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). , 2008, Leukemia.
[79] P. Marks,et al. Histone deacetylases and cancer: causes and therapies , 2001, Nature Reviews Cancer.
[80] I. Christensen,et al. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia , 2008, European journal of haematology.
[81] A. Papavassiliou,et al. FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities , 2006, Cancer Chemotherapy and Pharmacology.
[82] P. Atadja,et al. Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor–dependent human lung cancer cells , 2007, Molecular Cancer Therapeutics.
[83] Robert Brown,et al. A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced Solid Tumors , 2008, Clinical Cancer Research.
[84] E. Seto,et al. Acetylation and deacetylation of non-histone proteins. , 2005, Gene.
[85] C. Steidl,et al. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all‐trans retinoic acid in patients with acute myeloid leukemia , 2006, Cancer.
[86] K. Bhalla,et al. A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematologic Malignancies , 2006, Clinical Cancer Research.
[87] K. Luger. Structure and dynamic behavior of nucleosomes. , 2003, Current opinion in genetics & development.
[88] Fred Asselbergs,et al. Cloning and Functional Characterization of HDAC11, a Novel Member of the Human Histone Deacetylase Family* , 2002, The Journal of Biological Chemistry.
[89] M. Fishman,et al. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[90] S. Hövelmann,et al. Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial , 2007, British Journal of Cancer.
[91] M. Minden,et al. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. , 2008, Blood.
[92] C. Wittekind,et al. Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors. , 2008, World journal of gastroenterology.
[93] P. Marks,et al. The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid. , 2001, Cancer research.
[94] Michele Pallaoro,et al. HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics , 2007, Cell Research.
[95] I. Jurisica,et al. The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells , 2005, Leukemia.
[96] Gordon K Smyth,et al. Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma , 2008, Clinical Cancer Research.
[97] Jacques Côté,et al. The diverse functions of histone acetyltransferase complexes. , 2003, Trends in genetics : TIG.
[98] M. Ratain,et al. Phase I study of belinostat (PXD101) plus azacitidine (AZC) in patients with advanced myeloid neoplasms , 2008 .
[99] S. Isebaert,et al. A systematic assessment of radiation dose enhancement by 5-Aza-2'-deoxycytidine and histone deacetylase inhibitors in head-and-neck squamous cell carcinoma. , 2009, International journal of radiation oncology, biology, physics.
[100] N. Fortunati,et al. Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines. , 2007, Endocrine-related cancer.
[101] James Bradner,et al. Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90 , 2005, Journal of Biological Chemistry.
[102] M. K. Pflum,et al. Isoform-selective histone deacetylase inhibitors. , 2008, Chemical Society reviews.
[103] M. Jung,et al. Inhibitors of histone deacetylase as new anticancer agents. , 2001, Current medicinal chemistry.
[104] P. Marks,et al. Histone deacetylase inhibitors: discovery and development as anticancer agents , 2005, Expert opinion on investigational drugs.
[105] S. Grant,et al. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. , 2003, Cancer research.
[106] C. Schoch,et al. Clinical trial of valproic acid and all‐trans retinoic acid in patients with poor‐risk acute myeloid leukemia , 2005, Cancer.
[107] D. Lebwohl,et al. Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy , 2009, Journal of hematology & oncology.
[108] Ivan V. Gregoretti,et al. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. , 2004, Journal of molecular biology.
[109] P. Atadja,et al. The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells. , 2007, Blood.
[110] Jiang Wu,et al. Chemical regulation of epigenetic modifications: Opportunities for new cancer therapy , 2008, Medicinal research reviews.
[111] Hsiang-Yu Lin,et al. Targeting histone deacetylase in cancer therapy , 2006, Medicinal research reviews.
[112] W. Yeo,et al. The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines , 2010, Investigational New Drugs.
[113] W. Wilson,et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. , 2001, Blood.
[114] L. Siu,et al. Promising antitumor activity with MGCD0103, a novel isotype-selective histone deacetylase inhibitor. , 2008, Expert opinion on investigational drugs.
[115] P. Marks,et al. Histone deacetylase inhibitors and retinoic acids inhibit growth of human neuroblastoma in vitro. , 2000, Medical and pediatric oncology.
[116] Isabelle Paquin,et al. Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor. , 2008, Journal of medicinal chemistry.
[117] S. Bates,et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[118] Karl Mechtler,et al. Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins , 2001, Nature.
[119] S. Gay,et al. Epigenetic modifications in rheumatoid arthritis , 2008, Arthritis research & therapy.
[120] Z. Cao,et al. CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo , 2006, Molecular Cancer Therapeutics.
[121] P. Atadja,et al. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. , 2006, Cancer research.
[122] S. Shankar,et al. HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma , 2005, Oncogene.
[123] E. Sausville,et al. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[124] M. Horikoshi,et al. Simple histone acetylation plays a complex role in the regulation of gene expression. , 2006, Briefings in functional genomics & proteomics.
[125] H. Mackay,et al. A phase II trial of the histone deacetylase inhibitor belinostat (PXD101) in patients with platinum resistant epithelial ovarian tumors and micropapillary/borderline (LMP) ovarian tumors. A PMH phase II consortium trial , 2008 .
[126] Xiang-Jiao Yang,et al. Histone deacetylase inhibitors as novel anticancer therapeutics , 2008, Current oncology.
[127] V. Kiermer,et al. The emerging role of class II histone deacetylases. , 2001, Biochemistry and cell biology = Biochimie et biologie cellulaire.
[128] Suzanne F. Jones,et al. A phase I trial of romidepsin in combination with gemcitabine in patients with pancreatic and other advanced solid tumors , 2008 .
[129] K. Sakamoto,et al. The aggresome pathway as a target for therapy in hematologic malignancies. , 2008, Molecular genetics and metabolism.
[130] S. Shankar,et al. Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis. , 2008, Advances in experimental medicine and biology.
[131] Jorge Cortes,et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. , 2007, Blood.
[132] D. Liu,et al. Clinical advances in hypomethylating agents targeting epigenetic pathways. , 2010, Current cancer drug targets.
[133] R. Bociek,et al. Isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed/refractory classical Hodgkin Lymphoma (HL) , 2008 .
[134] Xue-Ru Wu,et al. The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo , 2007, Journal of Translational Medicine.
[135] K. Glaser,et al. Differential protein acetylation induced by novel histone deacetylase inhibitors. , 2004, Biochemical and biophysical research communications.
[136] Vigushin Dm,et al. Histone deacetylase inhibitors in cancer treatment. , 2002 .
[137] C. Van Waes,et al. Nuclear factor-κB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101 , 2007, Molecular Cancer Therapeutics.
[138] S. Ishii,et al. Increased Affinity of c-Myb for CREB-binding Protein (CBP) after CBP-induced Acetylation* , 2001, The Journal of Biological Chemistry.
[139] M. Rothenberg,et al. A Phase I and Pharmacokinetic Study of the Oral Histone Deacetylase Inhibitor, MS-275, in Patients with Refractory Solid Tumors and Lymphomas , 2008, Clinical Cancer Research.
[140] M. Sehested,et al. Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies , 2006, Molecular Cancer Therapeutics.
[141] M. Grever,et al. The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells , 2004, Leukemia.
[142] J. Dancey,et al. Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[143] Seon-Young Kim,et al. Evaluation of novel histone deacetylase inhibitors as therapeutic agents for colorectal adenocarcinomas compared to established regimens with the histoculture drug response assay , 2009, International Journal of Colorectal Disease.
[144] P. Atadja,et al. Hydroxamic Acid Analogue Histone Deacetylase Inhibitors Attenuate Estrogen Receptor-α Levels and Transcriptional Activity: A Result of Hyperacetylation and Inhibition of Chaperone Function of Heat Shock Protein 90 , 2007, Clinical Cancer Research.
[145] R. Kornberg,et al. Twenty-Five Years of the Nucleosome, Fundamental Particle of the Eukaryote Chromosome , 1999, Cell.